HC Q study #100
See all studies
Late treatment study
Alamdari et al., Tohoku J. Exp. Med., 2020, 252, 73-84, doi:10.1620/tjem.252.73 (Peer Reviewed)
Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Retrospective 396 patients in Iran 93% using HC Q, showing HC Q mortality RR 0.45, p = 0.028. HC Q was the only antiviral that showed a significant difference. Small number of control patients and subject to confounding by indication. Average admission delay 5.72 days.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.